INTERVENTION 1:	Intervention	0
Capecitabine	Intervention	1
capecitabine	CHEBI:31348	0-12
The starting dose of capecitabine was 3,000 mg (total daily dose) given in two divided daily doses for 14 days followed by 7 days of rest (1 cycle = 21 days). Missed doses were not substituted. Treatment was continued until unacceptable toxicity, disease progression, or withdrawal of consent.	Intervention	2
capecitabine	CHEBI:31348	21-33
disease	DOID:4,OGMS:0000031	247-254
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast	Eligibility	1
adenocarcinoma	DOID:299	55-69
breast	UBERON:0000310	77-83
Evidence of metastatic involvement (stage IV disease)	Eligibility	2
disease	DOID:4,OGMS:0000031	45-52
Patients must have measurable disease	Eligibility	3
disease	DOID:4,OGMS:0000031	30-37
At least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)	Eligibility	4
Treated brain metastases (surgery or radiation therapy) allowed if clinically stable	Eligibility	5
brain	UBERON:0000955	8-13
surgery	OAE:0000067	26-33
stable	HP:0031915	78-84
Patients with leptomeningeal disease are ineligible	Eligibility	6
disease	DOID:4,OGMS:0000031	29-36
Hormone receptor status:	Eligibility	7
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Not specified	Eligibility	8
PATIENT CHARACTERISTICS:	Eligibility	9
patient	HADO:0000008,OAE:0001817	0-7
Eastern Cooperative Oncology Group (ECOG) performance status 0-2	Eligibility	10
group	CHEBI:24433	29-34
Male or female	Eligibility	11
male	CHEBI:30780,PATO:0000384	0-4
male	CHEBI:30780,PATO:0000384	10-14
female	PATO:0000383	8-14
Menopausal status not specified	Eligibility	12
Absolute neutrophil count (ANC)  1,500/mm^3	Eligibility	13
Platelet count  100,000/mm^3	Eligibility	14
platelet count	CMO:0000029	0-14
Creatinine clearance > 50 mL/min	Eligibility	15
creatinine clearance	CMO:0000765	0-20
Fertile patients must use effective contraception	Eligibility	16
No history of another severe and/or life-threatening medical disease	Eligibility	17
history	BFO:0000182	3-10
severe	HP:0012828	22-28
disease	DOID:4,OGMS:0000031	61-68
No other active primary malignancy	Eligibility	18
active	PATO:0002354	9-15
Not pregnant or nursing	Eligibility	19
Negative pregnancy test	Eligibility	20
Patients with asymptomatic HIV infection are eligible	Eligibility	21
Liver dysfunction score  9	Eligibility	22
liver	UBERON:0002107	0-5
No pre-existing liver disease (i.e., cirrhosis or active viral hepatitis)	Eligibility	23
liver disease	DOID:409	16-29
cirrhosis	HP:0001394	37-46
active	PATO:0002354	50-56
viral hepatitis	HP:0006562,DOID:1884	57-72
No active gastrointestinal malabsorption illness	Eligibility	24
active	PATO:0002354	3-9
malabsorption	HP:0002024	27-40
No clinically significant cardiac disease, including the following:	Eligibility	25
disease	DOID:4,OGMS:0000031	34-41
Congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmias not well controlled with medication, or myocardial infarction within the past six months	Eligibility	26
congestive heart failure	HP:0001635,DOID:6000	0-24
coronary artery disease	DOID:3393	38-61
myocardial infarction	HP:0001658,DOID:5844	127-148
No prior unanticipated severe reaction to fluoropyrimidine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenase deficiency	Eligibility	27
severe	HP:0012828	23-29
hypersensitivity	GO:0002524,DOID:1205	74-90
dihydropyrimidine dehydrogenase deficiency	DOID:14218	117-159
No history of uncontrolled seizures or central nervous system disorders	Eligibility	28
history	BFO:0000182	3-10
central nervous system	UBERON:0001017	39-61
No significant history of noncompliance to medical regimens	Eligibility	29
history	BFO:0000182	15-22
No clinically significant psychiatric disability that would preclude study compliance	Eligibility	30
PRIOR CONCURRENT THERAPY:	Eligibility	31
No previous capecitabine	Eligibility	32
capecitabine	CHEBI:31348	12-24
Up to 3 prior cytotoxic regimens allowed for metastatic disease	Eligibility	33
disease	DOID:4,OGMS:0000031	56-63
Prior noncytotoxic therapy allowed (e.g., hormonal treatment or trastuzumab)	Eligibility	34
No other concurrent therapies intended to treat the primary condition including chemotherapy, biologic agents, or immunotherapy	Eligibility	35
condition	PDRO:0000129	60-69
No concurrent anti-estrogen therapy, radiation therapy, or investigational systemic therapy	Eligibility	36
anti-estrogen	CHEBI:50751	14-27
No other concurrent investigational drugs	Eligibility	37
No concurrent use of the following drugs: warfarin for full anticoagulation, cimetidine, or azidothymidine (AZT)	Eligibility	38
warfarin	CHEBI:10033	42-50
cimetidine	CHEBI:3699	77-87
Mini-dose warfarin for prophylaxis of central venous catheter thrombosis allowed	Eligibility	39
warfarin	CHEBI:10033	10-18
central	HP:0030645	38-45
thrombosis	DOID:0060903	62-72
At least 4 weeks since prior sorivudine or brivudine	Eligibility	40
sorivudine	CHEBI:32152	29-39
Concurrent use of bisphosphonates allowed if initiated before beginning study therapy	Eligibility	41
Concurrent use of megestrol acetate suspension as an appetite stimulant allowed	Eligibility	42
megestrol acetate	CHEBI:6723	18-35
suspension	BAO:0002104	36-46
Outcome Measurement:	Results	0
Response Rate	Results	1
rate	BAO:0080019	9-13
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	Results	2
target	BAO:0003064	76-82
target	BAO:0003064	160-166
target	BAO:0003064	252-258
diameter	PATO:0001334	240-248
Time frame: Participants were followed to progression, evaluated every 12 weeks	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Capecitabine	Results	5
capecitabine	CHEBI:31348	17-29
Arm/Group Description: The starting dose of capecitabine was 3,000 mg (total daily dose) given in two divided daily doses for 14 days followed by 7 days of rest (1 cycle = 21 days). Missed doses were not substituted. Treatment was continued until unacceptable toxicity, disease progression, or withdrawal of consent.	Results	6
capecitabine	CHEBI:31348	44-56
disease	DOID:4,OGMS:0000031	270-277
Overall Number of Participants Analyzed: 21	Results	7
Measure Type: Number	Results	8
Unit of Measure: participants  21	Results	9
Adverse Events 1:	Adverse Events	0
Total: 2/26 (7.69%)	Adverse Events	1
Death  [1]2/26 (7.69%)	Adverse Events	2
death	OAE:0000632	0-5
